Live Breaking News & Updates on Fusion Pharmaceuticals Stock

Stay updated with breaking news from Fusion pharmaceuticals stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Fusion Pharmaceuticals (NASDAQ:FUSN) Sees Large Volume Increase

Fusion Pharmaceuticals (NASDAQ:FUSN) Sees Large Volume Increase
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United-states , Canada , Wellington , New-zealand-general , New-zealand , Raymond-james , Nasdaq , Jennison-associates , News-ratings-for-fusion-pharmaceuticals-daily , Wellington-management-group , Institutional-trading-of-fusion-pharmaceuticals , Fusion-pharmaceuticals-inc

Q1 2024 Earnings Forecast for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Issued By William Blair

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Equities research analysts at William Blair lifted their Q1 2024 EPS estimates for shares of Fusion Pharmaceuticals in a research report issued to clients and investors on Thursday, March 21st. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of ($0.39) […] ....

Canada , United-states , Raymond-james , William-blair , Forefront-analytics , Eagle-health-investments , News-ratings-for-fusion-pharmaceuticals-daily , Hedge-funds-weigh-in-on-fusion-pharmaceuticals , Fusion-pharmaceuticals-stock , Fusion-pharmaceuticals , Fusion-pharmaceuticals-inc , Yarbrough-capital

Fusion Pharmaceuticals (NASDAQ:FUSN) Reaches New 12-Month High at $21.32

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report)’s stock price hit a new 52-week high on Monday . The company traded as high as $21.32 and last traded at $21.29, with a volume of 225039 shares traded. The stock had previously closed at $21.24. Analysts Set New Price Targets Several brokerages have issued reports on […] ....

Canada , United-states , Fusion-pharmaceuticals-inc , News-ratings-for-fusion-pharmaceuticals-daily , Institutional-trading-of-fusion-pharmaceuticals , Fusion-pharmaceuticals-stock , Fusion-pharmaceuticals-company-profile , Renaissance-technologies , Royal-bank , Nasdaq , Tower-research-capital

Truist Financial Reaffirms Hold Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)

Truist Financial Reaffirms Hold Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada , United-states , Raymond-james , Schonfeld-strategic-advisors , Renaissance-technologies , Fusion-pharmaceuticals , Tower-research-capital , Fusion-pharmaceuticals-stock , Hedge-funds-weigh-in-on-fusion-pharmaceuticals , Analyst-recommendations-for-fusion-pharmaceuticals , Millennium-management , Fusion-pharmaceuticals-inc

SVB Leerink Reiterates "Market Perform" Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)

SVB Leerink reaffirmed their market perform rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $21.00 target price on the stock, up from their prior target price of $17.00. Several other equities analysts have also commented on […] ....

United-states , Canada , William-blair , Raymond-james , Hermes-inc , Fusion-pharmaceuticals-stock , Citadel-advisors , News-ratings-for-fusion-pharmaceuticals-daily , Institutional-investors-weigh-in-on-fusion-pharmaceuticals , Renaissance-technologies , Fusion-pharmaceuticals , Millennium-management